310 Mira Street, Stavropol, Russia, 355017
+7 8652 352524; +7 8652 353229.
+7 8652 352524.
The journal is included into The list of leading scientific periodicals.
A pathological morphological assessment of the periodontal tissues was carried out against the background of the administration of bisphosphonates to rats after preliminary modeling of metabolic disorders by ovariectomy. It has been established that ovaectomy promotes the development of osteonecrosis of the lower jaw of animals after administration of zoledronic acid. Two months after the administration of the drug, ovariectomized rats showed varying degrees of severity and signs of rarefaction of the alveolar bone with a decrease in the number of collagen fibers of the periodontal ligament and an increase in cellular infiltration with histiocytes and fibroblasts. The signs of coagulation necrosis with the subsequent formation of a pronounced chronic inflammatory process and partial lysis of the affected bone area were revealed. In control animals and rats without oophorectomy, the introduction of bisphosphonates did not cause such changes in the mandible bone. The development of osteonecrosis of the jaws against the background of the use of bisphosphonates may be accompanied by inflammatory processes and necrosis against the background of the already existing metabolic changes in periodontal tissues.
1. Сhukir T., Liu Y., Farooki A. Antiresorptive Agents’ Boneprotective And Adjuvant Effects In Postmenopausal Women With Early Breast Cancer. British Journal of Clinical Pharmacology. 2018. https://doi.org/10.11/bcp.13834
2. McGowan K., McGowan T., Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Diseases. 2018;24(4):527-536. https://doi.org/10.11/odi.12708
3. Stavropoulos A., Bertl K., Pietschmann P., Pandis N., Schiødt M. [et al.]. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis. Clinical Oral Implants Research. 2018;29(Suppl 18):54-92. https://doi.org/10.1016/j.joms.2008.12.007
4. Sirak S. V., Shchetinin E. V. Prevention of complications in patients suffering from pathological mandibular fractures due to bisphosphonate-associated osteonecrosis. Research Journal Pharmaceutical, Biological and Chemical Science. 2015;6(5):1678-1684
5. Favia G., Tempesta A., Limongelli L., Crincoli V., Piattelli A. [et al.]. Metastatic Breast Cancer In Medication-Related Osteonecrosis Around Mandibular Implants. American journal of case reports. 2015;16:621-6. https://doi.org/10.12659/ajcr.894162
6. Sanchis J. M., Bagán J. V., Murillo J., Díaz J. M., Asensio l. Risk of developing BRONJ among patients
exposed to intravenous bisphosphonates following tooth extraction. Quintessence international. 2014;45(9):769-77. https://doi.org/10.3290/j.qi.a32243
7. Giovannacci I., Meleti M., Manfredi M., Mortellaro C., Greco Lucchina A. [et al.]. Medication-Related Osteonecrosis Of The Jaw Around Dental Implants: Implant Surgery-Triggered Or Implant Presence-Triggered Osteonecrosis? Journal of Craniofacial surgery. 2016;27(3):697-701. https://doi.org/10.1097/scs.0000000000002564
8. Rao N. J., Wang J. Y., Yu R. Q., Leung Y. Y., Zheng l. W. Role of periapical diseases in medication-
Related osteonecrosis of the jaws. Biomed research International. 2017;2017:1560175. https://doi.org/10.1155/2017/1560175
9. Hoff A. O., Toth B., Hu M., Hortobagyi G. N., Gagel R. F. Epidemiology and risk factors for osteonecrosis of the jaw In cancer patients. Annals of the New York Academy Of Sciences. 2011;1218:47-54. https://doi.org/10.11/j.1749-6632.2010.05771.x
Keywords: osteonecrosis of the jaws, bisphosphonates, periodontal tissues